Letter to the Editor re: Evaluation of the Clinical Effects of Abobotolinum Toxin A (Dysport) Injection in the Treatment of Neurogenic Lower Urinary Tract Dysfunction
Urology Journal,
Vol. 20 No. 04 (2023),
2 October 2023
,
Page 287-288
https://doi.org/10.22037/uj.v19i.7345
Abstract
- neurogenic. bladder
- questionnaire
How to Cite
References
Sharifiaghdas F, Taheri M, Borumandnia N et al. Evaluation of the Clinical Effects of Abobotolinum Toxin A (Dysport) Injection in the Treatment of Neurogenic Lower Urinary Tract Dysfunction. Urology Journal 2022; 1: 63-68
Uebersax J, Wyman J, Shumaker S, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn 1995; 14: 131-9
Costa P, Costa P, Perrouin-Verbe B, et al. Quality of Life in Spinal Cord Injury Patients with Urinary Difficulties. European Urology 2001; 39: 107-113
Bonniaud V, Bryant D, Parratte B, et al. Development and Validation of the Short Form of a Urinary Quality of Life Questionnaire: SF-Qualiveen. The Journal of Urology 2008; 180: 2592-2598
Floyd MS, Jr. and Khadr RN. Role of gentamicin in reducing urinary tract infections in patients with neurogenic bladder. Canadian Urological Association journal Journal de l'Association des urologues du Canada 2017; 11: 427-428. 2017/11/01
Cruz F, Herschorn S, Aliotta P, at al. Efficacy and safety of onabotulinumtoxin A in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial, Eur Urol, 2011; 60: 742-75
Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxin A for urinary incontinence from neurogenic detrusor overactivity. J Urol, 2012; 187: 2131-2139
- Abstract Viewed: 323 times
- 7345/pdf Downloaded: 228 times